Liraglutide (Victoza) vs orforglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Victoza) | orforglipron |
|---|---|---|
| HbA1c, change | -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
| -1.4% vs -0.1%−1.3 vs placeboNCT0597194014 other results
|
| Body weight, change (kg) | -2.5 vs -0.9−1.6 vs placeboNCT0154121522 other results
| -7.3 vs -1.3−6 vs placeboNCT059719407 other results
|
| HbA1c below 7% | 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
| 79.0% vs 37.1%+41.9 vs placeboNCT059719407 other results
|
| Fasting plasma glucose, change | -1.6 vs 1.0−2.6 vs placeboNCT0154121521 other results
| -2.0 vs -1.1−0.9 vs placeboNCT044264744 other results
|
| 3-point MACE (% with event) | 13% vs 14.9%−1.9 vs placeboNCT01179048 | —Not posted · NCT05803421 |
HbA1c, change
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -0.7% vs 0.7% NCT01541215
- -2.0% vs -1.7% NCT02501161
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
- orforglipron
- -1.4% vs -0.1%−1.3 vs placeboNCT05971940
14 other results
- -1.6% vs -0.1% NCT05971940
- -1.3% vs -0.1% NCT05971940
- -2.0% vs -0.4% NCT05048719
- -1.9% vs -0.4% NCT05048719
- -1.2% vs -0.4% NCT05048719
- -2.1% vs -0.4% NCT05048719
- -1.8% vs -0.4% NCT05048719
- -2.0% vs -1.1% NCT05048719
- -1.9% vs -1.1% NCT05048719
- -1.2% vs -1.1% NCT05048719
- -2.1% vs -1.1% NCT05048719
- -1.8% vs -1.1% NCT05048719
- -1.7% vs -0.5% NCT05872620
- 1.7% vs 0.8% NCT06192108
Body weight, change (kg)
- Liraglutide (Victoza)
- -2.5 vs -0.9−1.6 vs placeboNCT01541215
22 other results
- -2.3 vs 1.0 NCT01541215
- -2.8 vs 0.9 NCT00318461
- -2.9 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 1.2 vs 3 NCT02501161
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
- orforglipron
- -7.3 vs -1.3−6 vs placeboNCT05971940
7 other results
- -5.5 vs -1.3 NCT05971940
- -4.4 vs -1.3 NCT05971940
- -9.5 vs -2.2 NCT05048719
- -6.5 vs -2.2 NCT05048719
- -3.7 vs -2.2 NCT05048719
- -10.1 vs -2.2 NCT05048719
- -9.7 vs -2.2 NCT05048719
HbA1c below 7%
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
- orforglipron
- 79.0% vs 37.1%+41.9 vs placeboNCT05971940
7 other results
- 81.3% vs 37.1% NCT05971940
- 78.2% vs 37.1% NCT05971940
- 92.8% vs 24.3% NCT05048719
- 78.9% vs 24.3% NCT05048719
- 65.2% vs 24.3% NCT05048719
- 95.8% vs 24.3% NCT05048719
- 91.2% vs 24.3% NCT05048719
Fasting plasma glucose, change
- Liraglutide (Victoza)
- -1.6 vs 1.0−2.6 vs placeboNCT01541215
21 other results
- -1.1 vs 0.8 NCT01541215
- -1.2 vs -0.6 NCT00318461
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -3.9 vs -3.7 NCT02501161
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.6 vs -3.5 NCT03172494
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
- orforglipron
- -2.0 vs -1.1−0.9 vs placeboNCT04426474
4 other results
- -3 vs -1.1 NCT04426474
- -2.9 vs -1.1 NCT04426474
- -2.4 vs -1.1 NCT04426474
- -2.3 vs -1.1 NCT04426474
3-point MACE (% with event)
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- orforglipron
- —Not posted · NCT05803421
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Liraglutide (Victoza): 8 of 8 rows · orforglipron: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) Rows use multiple source trials | orforglipron Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wka,b,c,d NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -2.13% (n=125) @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-1.97% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -1.71% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 61.7% (n=162) vs 26.3% (n=175) Sitagliptin @ 26wke,b,c,f NCT02008682 · Phase 4 · registry result, not featured evidence 1 other source trial34.36% (n=195) vs 9.47% (n=95) placebo @ 26wk Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 68.91% (n=119) vs 18.56% (n=97) placebo @ 40wk36 mga,e,b,c,f NCT05971940 · Phase 3 · registry result, not featured evidence show 2 more doses68.75% (n=112) vs 18.56% (n=97) placebo @ 40wk12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 66.39% (n=119) vs 18.56% (n=97) placebo @ 40wk3 mg NCT05971940 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -1.95 vs -3.35 placebo mmHg @ 26wkb,c,f NCT02964247 · Phase 3 · registry result, not featured evidence | -6 vs -0.5 placebo mmHg @ 40wk36 mga,b,c,f NCT05971940 · Phase 3 · registry result, not featured evidence show 2 more doses-6.1 vs -0.5 placebo mmHg @ 40wk12 mg NCT05971940 · Phase 3 · registry result, not featured evidence -3.2 vs -0.5 placebo mmHg @ 40wk3 mg NCT05971940 · Phase 3 · registry result, not featured evidence |
| Weight percent change · % of baseline | -7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkg,c,h NCT01234649 · Phase 3 · registry result, not featured evidence · combination | -9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mgg,c,h NCT05872620 · Phase 3 · sponsor-reported, not registry data |
| Dropout rate | 21.1%1.8 mg dailyi NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence | 6.7%36 mgj NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results5.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 5.3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3.5%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 8.8%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 6.3%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 7.4%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 11.8%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.7%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 7.8%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 9.4%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 57.1%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 12%1.8 mg dailyi NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence | 2.2%36 mgj NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results4.4%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.5%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.4%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0.7%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.6%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 35.7%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 6.6%1.8 mg dailyi NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence | 4.5%36 mgj NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results2.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 2.8%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.1%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.6%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2.9%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 1.8%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 5.9%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.1%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%3 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 1.8 mg dailyi nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence | 36 mgj constipation 29.1% nausea 27.6% nasopharyngitis 16.4% NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results12 mg constipation 30.4% nasopharyngitis 22.2% nausea 19.3% NCT06010004 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 17.4% constipation 16.7% nausea 12.9% NCT06010004 · Phase 3 · registry result, not featured evidence 36 mg diarrhoea 25.5% (placebo 9.4%) diabetic retinopathy 17% (placebo 15.2%) nausea 17% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 12 mg diarrhoea 21.2% (placebo 9.4%) dyspepsia 21.2% (placebo 7.2%) nausea 19% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 3 mg diarrhoea 18.9% (placebo 9.4%) diabetic retinopathy 14.7% (placebo 15.2%) nausea 12.6% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 36 mg nausea 37% (placebo 5.5%) vomiting 33.3% (placebo 1.8%) diarrhoea 25.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 36 mg nausea 26.5% (placebo 5.5%) vomiting 20.6% (placebo 1.8%) eructation 8.8% (placebo 0%) NCT05048719 · Phase 2 · registry result, not featured evidence 12 mg nausea 37.5% (placebo 5.5%) vomiting 21.4% (placebo 1.8%) diarrhoea 16.1% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 23.5% (placebo 5.5%) diarrhoea 21.6% (placebo 7.3%) constipation 13.7% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg vomiting 35.5% (placebo 1.8%) diarrhoea 29% (placebo 7.3%) nausea 29% (placebo 5.5%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 28.1% (placebo 7.3%) nausea 25% (placebo 5.5%) vomiting 21.9% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 24 mg nausea 34% (placebo 5.5%) vomiting 27.7% (placebo 1.8%) diarrhoea 14.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 55.6% (placebo 25%) constipation 33.3% (placebo 0%) vomiting 22.2% (placebo 25%) NCT05086445 · Phase 1 · registry result, not featured evidence 2 mg vomiting 40% (placebo 25%) nausea 30% (placebo 25%) abdominal distension 20% (placebo 0%) NCT05086445 · Phase 1 · registry result, not featured evidence 3/6/12/15 mg QD nausea 50% (placebo 5.9%) vomiting 50% (placebo 0%) decreased appetite 40% (placebo 11.8%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21 mg QD nausea 42.9% (placebo 5.9%) decreased appetite 28.6% (placebo 11.8%) covid-19 21.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21/27 mg QD decreased appetite 55.6% (placebo 11.8%) vomiting 55.6% (placebo 0%) nausea 33.3% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9 mg QD vomiting 55.6% (placebo 0%) decreased appetite 44.4% (placebo 11.8%) nausea 44.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9/21/36/45 mg QD nausea 77.8% (placebo 5.9%) decreased appetite 66.7% (placebo 11.8%) vomiting 55.6% (placebo 0%) NCT04426474 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 32 weeks versus 52 weeks.
- eTrial phases differ: Phase 4 versus Phase 3.
- fAssessment timepoints differ: 26 weeks versus 40 weeks.
- gPopulation context differs: registered conditions differ.
- hAssessment timepoints differ: 84 weeks versus 72 weeks.
- iPopulation comparability has not been reviewed for 32 of these studies.
- jPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
show 1 more result
show 8 more results
show 7 more results
show 3 more results
show 1 more result
show 2 more results
show 8 more results
+ 121 further endpoints in the CSV export.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 7 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · orforglipron's landscape